Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

von Kitano, Shigehisa, Shimizu, Toshio, Koyama, Takafumi, Ebata, Takahiro, Iwasa, Satoru, Kondo, Shunsuke, Shimomura, Akihiko, Fujiwara, Yutaka, Yamamoto, Noboru, Paccaly, Anne, Li, Siyu, Rietschel, Petra, Sims, Tasha
Veröffentlicht in Cancer Chemother Pharmacol (2020)

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

von Schwartz, Gary K, Tap, William D, Qin, Li-Xuan, Livingston, Michael B, Undevia, Samir D, Chmielowski, Bartosz, Agulnik, Mark, Schuetze, Scott M, Reed, Damon R, Okuno, Scott H, Ludwig, Joseph A, Keedy, Vicki, Rietschel, Petra, Kraft, Andrew S, Adkins, Douglas, Van Tine, Brian A, Brockstein, Bruce, Yim, Vincent, Bitas, Christiana, Abdullah, Abdul, Antonescu, Cristina R, Condy, Mercedes, Dickson, Mark A, Vasudeva, Shyamprasad Deraje, Ho, Alan L, Doyle, L Austin, Chen, Helen X, Maki, Robert G
Veröffentlicht 2013